These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27421978)

  • 1. Factors associated with fractures in HIV-infected persons: which factors matter?
    Gedmintas L; Wright EA; Dong Y; Lehmann E; Katz JN; Solomon DH; Losina E
    Osteoporos Int; 2017 Jan; 28(1):239-244. PubMed ID: 27421978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis-Related Fractures in HIV-Infected Patients Receiving Long-Term Tenofovir Disoproxil Fumarate: An Observational Cohort Study.
    Komatsu A; Ikeda A; Kikuchi A; Minami C; Tan M; Matsushita S
    Drug Saf; 2018 Sep; 41(9):843-848. PubMed ID: 29623648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of tenofovir disoproxil fumarate exposure with chronic kidney disease and osteoporotic fracture in US veterans with HIV.
    Sutton SS; Magagnoli J; Hardin JW; Hsu LI; Beaubrun A; Majethia S; Cummings TH
    Curr Med Res Opin; 2020 Oct; 36(10):1635-1642. PubMed ID: 32856940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort.
    Borges ÁH; Hoy J; Florence E; Sedlacek D; Stellbrink HJ; Uzdaviniene V; Tomazic J; Gargalianos-Kakolyris P; Schmid P; Orkin C; Pedersen C; Leen C; Pradier C; Mulcahy F; Ridolfo AL; Staub T; Maltez F; Weber R; Flamholc L; Kyselyova G; Lundgren JD; Mocroft A;
    Clin Infect Dis; 2017 May; 64(10):1413-1421. PubMed ID: 28329090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
    Nkhoma ET; Rosenblatt L; Myers J; Villasis-Keever A; Coumbis J
    PLoS One; 2016; 11(12):e0166982. PubMed ID: 27941989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir and bone health.
    Grant PM; Cotter AG
    Curr Opin HIV AIDS; 2016 May; 11(3):326-32. PubMed ID: 26859637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
    Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
    J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate.
    Medland NA; Chow EP; Walker RG; Chen M; Read TR; Fairley CK
    Int J STD AIDS; 2018 Mar; 29(3):227-236. PubMed ID: 28764611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir exposure alters associations of serum bicarbonate with chronic kidney disease risk in HIV-infected veterans.
    Kim JE; Scherzer R; Estrella MM; Ix JH; Shlipak MG
    AIDS; 2016 Apr; 30(7):1049-57. PubMed ID: 26760455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.
    Bedimo R; Maalouf NM; Zhang S; Drechsler H; Tebas P
    AIDS; 2012 Apr; 26(7):825-31. PubMed ID: 22301411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
    Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
    Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
    Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study.
    Jotwani V; Scherzer R; Estrella MM; Jacobson LP; Witt MD; Palella FJ; Macatangay B; Bennett M; Parikh CR; Ix JH; Shlipak MG
    Am J Kidney Dis; 2016 Oct; 68(4):571-581. PubMed ID: 27287300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
    Grant PM; Kitch D; McComsey GA; Tierney C; Ha B; Brown TT
    HIV Clin Trials; 2015; 16(2):66-71. PubMed ID: 25872972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate.
    Giacomet V; Maruca K; Ambrosi A; Zuccotti GV; Mora S
    Int J Antimicrob Agents; 2017 Sep; 50(3):365-370. PubMed ID: 28689877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Kidney Injury, Risk Factors, and Prognosis in Hospitalized HIV-Infected Adults in South Africa, Compared by Tenofovir Exposure.
    Seedat F; Martinson N; Motlhaoleng K; Abraham P; Mancama D; Naicker S; Variava E
    AIDS Res Hum Retroviruses; 2017 Jan; 33(1):33-40. PubMed ID: 27478997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
    Rokx C; Alshangi H; Verbon A; Zietse R; Hoorn EJ; Rijnders BJ
    J Infect Dis; 2016 Feb; 213(4):561-8. PubMed ID: 26401025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.
    Kim-Chang JJ; Wilson L; Chan C; Fischer B; Venturi G; Goodenow MM; Aldrovandi G; Weber TJ; Sleasman JW;
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):746-754. PubMed ID: 31115244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
    Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
    Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy.
    Biagi M; Badowski M; Chiampas T; Young J; Vaughn P; Shicker L; Patel M
    Int J STD AIDS; 2016 Aug; 27(9):808-11. PubMed ID: 26378193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.